Dr. Lal Path Labs Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 30 Jul 2026

Company page: Dr. Lal Path Labs share price, financials & guidance record

Dr. Lal Path Labs reported a strong Q1 FY27, with revenue growing 19.1% and PAT up 27.2%, driven by robust patient and sample volume growth and improved revenue per patient. The company expanded its test portfolio, enhanced patient experience through digital initiatives, and made strategic acquisitions in Ghana and India. Management expressed confidence in sustaining growth, with a focus on reinvestment and international expansion.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 19.1%, net profit up 26.9% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	660	597	603	670	731 +11%	660 +11%	703 +17%	798 +19%
Expenses	458	443	434	478	506	480	516	550
EBITDA	202	154	169	192	224 +11%	179 +16%	187 +11%	248 +29%
Margin	31%	26%	28%	29%	31%	27%	27%	31%
Other income	22	25	26	28	25	-6	24	32
Interest	6	5	5	5	5	7	6	6
Depreciation	35	36	36	35	40	42	45	44
Profit before tax	183	138	153	181	204 +11%	124 −10%	160 +5%	229 +27%
Tax rate	29%	29%	-1%	26%	25%	26%	17%	25%
Net profit	131	98	156	134	152 +16%	91 −7%	132 −15%	170 +27%
EPS	7.73	5.78	9.26	7.90	8.99	5.40	7.84	10.11

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls